

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 November 2024 (28.11.2024)



(10) International Publication Number
WO 2024/243085 A3

(51) International Patent Classification:

A61K 47/65 (2017.01) A61P 35/00 (2006.01)
A61K 47/68 (2017.01)

(21) International Application Number:

PCT/US2024/030085

(22) International Filing Date:

17 May 2024 (17.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/503,387	19 May 2023 (19.05.2023)	US
63/535,991	31 August 2023 (31.08.2023)	US
63/606,521	05 December 2023 (05.12.2023)	US
63/558,052	26 February 2024 (26.02.2024)	US

(71) Applicant: **SOLVE THERAPEUTICS, INC.** [US/US];
11045 Roselle Street, Suite 130, San Diego, California
92121 (US).

(72) Inventors: **LANNUTTI, Brian**; 11045 Roselle Street,
Suite 130, San Diego, California 92121 (US). **WATKINS,
Jeff**; 11045 Roselle Street, Suite 130, San Diego, California
92121 (US). **JESSEN, Katti**; 11045 Roselle Street, Suite
130, San Diego, California 92121 (US).

(74) Agent: **MARTINEZ, Jose** et al.; WILSON SONSINI
GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO
ALTO, California 94304-1050 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))


(88) Date of publication of the international search report:

13 March 2025 (13.03.2025)



WO 2024/243085 A3

(54) Title: DRUG-LINKERS AND DRUG CONJUGATES



(57) Abstract: Conjugates And Uses Thereof. Provided herein is a Drug-Linker of Formula (X), or a pharmaceutically acceptable salt thereof, wherein the variables of Formula (X) are as defined in the application. Conjugates of such compounds can be useful as anti-cancer agents.